The Hidden Cardiovascular Risk Factor: Why Inflammation Matters for Heart Health

May 4, 2026
Contributing Authors: Team TRILITY / ACEND

For decades, the public conversation around heart disease has centered on four familiar risk factors: high blood pressure, smoking, elevated LDL cholesterol, and type 2 diabetes. These remain critically important. They are measurable, modifiable, and strongly associated with cardiovascular risk. But they do not explain every case.

A growing body of cardiovascular science points to another powerful driver: chronic inflammation.

Scientific American recently highlighted this shift in cardiovascular thinking, describing how immune system overactivation may help explain why some people experience heart attacks or other cardiovascular events despite not fitting the classic high-risk profile. The article summarized a major evolution in cardiology: atherosclerosis is not simply a “clogged pipe” problem. It is increasingly understood as an inflammatory disease process involving cholesterol, immune cells, oxidative stress, vascular injury, and unresolved immune signaling. 

This matters because heart disease is not only about what accumulates in the arteries. It is also about how the body responds to that accumulation.

From “Clogged Pipes” to Inflamed Arteries

The old model of atherosclerosis was mechanical: cholesterol builds up, arteries narrow, blood flow becomes restricted, and eventually a heart attack or stroke occurs. That model is partly true, but incomplete.

The newer model is more dynamic. LDL cholesterol can enter the arterial wall, become modified, and contribute to plaque formation. As plaque develops, immune cells move into the area. Macrophages attempt to engulf lipid deposits, cellular debris, and cholesterol-rich material. Over time, these immune cells can become overloaded, die, and contribute to the unstable core of a plaque.

Researchers have also shown that cholesterol can form sharp crystalline structures within plaques. These cholesterol crystals may contribute to arterial wall injury and inflammatory signaling, including activation of inflammasome pathways linked to interleukin-1 beta, or IL-1β. 

This is where inflammation becomes central. The immune system is designed to respond to injury, infection, and danger signals. But in the arterial wall, the immune response may not resolve cleanly. Instead of turning off, it can persist for years. The result is a chronic inflammatory environment that may make plaques more unstable and more likely to rupture.

When a plaque ruptures, the body responds as if an injury has occurred. Blood clotting is activated. If the clot blocks blood flow to the heart or brain, the result can be a heart attack or stroke.

CRP: A Signal That the Fire Is Burning

One of the most studied markers of systemic inflammation is C-reactive protein, often measured as high-sensitivity C-reactive protein, or hsCRP.

Paul Ridker and colleagues helped establish hsCRP as a meaningful cardiovascular risk marker. In a landmark New England Journal of Medicine study, baseline CRP predicted future myocardial infarction and stroke risk in apparently healthy men. Another major study in women found that hsCRP was a strong predictor of future cardiovascular events. 

The JUPITER trial further changed the conversation. It enrolled nearly 18,000 people with low LDL cholesterol but elevated hsCRP. Participants treated with rosuvastatin had reductions in both LDL cholesterol and hsCRP, along with fewer vascular events. 

The implication was important: even when LDL cholesterol appears controlled or “normal,” inflammatory risk may still matter.

That idea has now moved closer to mainstream clinical practice. In 2025, the American College of Cardiology published a scientific statement on inflammation and cardiovascular disease and recommended broader use of hsCRP for cardiovascular risk assessment, including in both primary and secondary prevention contexts. 

For consumers, this does not mean hsCRP replaces cholesterol testing, blood pressure monitoring, glucose assessment, or physician-guided risk evaluation. It means inflammation may be one more important part of the cardiovascular risk picture.

Anti-Inflammatory Cardiology Is Emerging

The inflammation hypothesis became more persuasive when therapies targeting inflammation showed cardiovascular effects.

The CANTOS trial tested canakinumab, a monoclonal antibody targeting IL-1β, in more than 10,000 patients with prior myocardial infarction and elevated hsCRP. The trial showed that lowering inflammation through this pathway reduced major cardiovascular events without lowering LDL cholesterol. 

Colchicine, an older anti-inflammatory drug used for gout, has also been studied in cardiovascular disease. In the LoDoCo2 trial, low-dose colchicine reduced cardiovascular events in patients with chronic coronary disease. In 2023, the FDA approved low-dose colchicine to reduce cardiovascular risk in certain patients with established atherosclerotic disease or multiple cardiovascular risk factors, according to the Scientific American summary and related cardiovascular coverage. 

However, the story is not settled. A 2025 trial of colchicine after acute myocardial infarction did not show the same benefit, and gastrointestinal tolerability remains a concern. 

This is the reality of science: inflammation matters, but not every anti-inflammatory intervention works the same way in every patient, at every stage of disease, or with the same safety profile.

What This Means for Everyday Cardiovascular Resilience

The cardiovascular system is not isolated from the rest of the body. It is influenced by metabolic health, gut barrier integrity, oxidative stress, immune tone, sleep, stress physiology, nutrient status, and diet quality.

That is why inflammation-focused cardiovascular wellness should not be reduced to one drug, one nutrient, or one biomarker. A more useful model is systems support.

The practical goal is not to suppress the immune system. Inflammation is necessary for healing. The goal is to support a healthier inflammatory tone: a state in which immune responses activate appropriately, resolve efficiently, and do not remain chronically elevated.

Key lifestyle and nutrition pillars include:

Eating a polyphenol-rich diet from colorful plants, herbs, spices, tea, berries, cocoa, and deeply pigmented fruits and vegetables.

Supporting healthy lipid, glucose, and blood pressure patterns through diet, movement, sleep, and physician-guided care.

Addressing gut-immune signaling through fiber, prebiotics, probiotics, and microbiome-supportive nutrients.

Reducing oxidative stress through antioxidant-rich dietary patterns and avoidance of smoking, excess alcohol, and ultra-processed dietary patterns.

Discussing hsCRP, LDL-C, ApoB, Lp(a), blood pressure, fasting glucose, HbA1c, and other cardiovascular markers with a qualified healthcare professional.

How ACEND Supports Inflammatory Balance

ACEND-CI is formulated for the dietary management of chronic inflammation. While it is not a cardiovascular drug and is not intended to diagnose, treat, cure, or prevent heart disease, its ingredient architecture aligns with several nutritional priorities relevant to healthy inflammatory tone.

ACEND brings together polyphenols, bioactives, micronutrients, minerals, prebiotic fiber, and probiotic support in a systems-minded formula.

Polyphenols are especially relevant because they are not simply antioxidants. They interact with redox signaling, inflammatory pathways, endothelial biology, and the gut microbiome. ACEND-CI includes polyphenol and flavonoid compounds such as quercetin, epicatechin, taxifolin, luteolin, dihydromyricetin, and grape seed proanthocyanidins.

Quercetin has been studied in relation to cardiometabolic markers and inflammatory signaling, with meta-analytic evidence suggesting potential effects on some cardiometabolic parameters. Epicatechin, a flavanol found in cocoa and tea, has been studied for vascular and endothelial function, with randomized trial literature suggesting relevance to cardiometabolic health. 

ACEND-CI also contains astaxanthin, a carotenoid known for antioxidant and inflammation-related activity. Reviews and clinical research have explored astaxanthin in relation to oxidative stress, inflammation, lipid parameters, and cardiovascular risk biology. 

Curcumin is another major inflammation-related bioactive. ACEND-CI uses CurcuRouge®, a highly bioavailable curcumin technology. Curcumin has been extensively studied for inflammatory markers, including CRP, and randomized-trial meta-analyses suggest it may support inflammatory balance as part of broader nutritional strategies. 

Beyond polyphenols and bioactives, ACEND-CI includes vitamin D3, vitamin K2, magnesium, zinc, selenium, potassium, calcium, vitamin C, vitamin E, niacinamide, and betaine. These nutrients do not “treat” heart disease, but they participate in biological systems relevant to immune regulation, antioxidant defense, methylation, vascular function, electrolyte balance, and metabolic resilience.

The formula also includes organic gum acacia and Bacillus coagulans. This matters because the gut is a major immune interface. A healthier gut-immune axis may help support more stable systemic inflammatory tone.

The Bigger Lesson: Heart Health Is Whole-Body Health

The emerging cardiovascular inflammation story should not make people ignore cholesterol, blood pressure, smoking, glucose, body composition, or exercise. Those remain foundational. LDL cholesterol still matters. Blood pressure still matters. Diabetes risk still matters. Smoking still matters.

But inflammation helps explain why cardiovascular risk can persist even when traditional numbers look acceptable.

The future of heart health is likely to be more integrated: lipids plus inflammation, vascular biology plus immune signaling, metabolic health plus gut health, prevention plus precision biomarkers.

For ACEND, this is exactly the kind of systems biology the brand was built around. Chronic inflammation is rarely isolated to one organ. It moves through immune networks, metabolic signaling, gut barrier function, oxidative stress pathways, and vascular communication. Supporting the system means nourishing the pathways that help the body maintain balance.

Therefore, the hidden lesson of heart disease may not be that inflammation replaces cholesterol as the villain. It is that cardiovascular health is not a single-pathway problem. It is a whole-body resilience problem.

References

Scientific American. “The Hidden Cause of Heart Disease Is Inflammation.” Melinda Wenner Moyer. Published April 14, 2026. 

Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. “Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men.” New England Journal of Medicine. 1997. 

Ridker PM, Hennekens CH, Buring JE, Rifai N. “C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women.” New England Journal of Medicine. 2000. 

Ridker PM, Danielson E, Fonseca FAH, et al. “Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein.” New England Journal of Medicine. 2008. 

Ridker PM, Everett BM, Thuren T, et al. “Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.” New England Journal of Medicine. 2017. 

Nidorf SM, Fiolet ATL, Mosterd A, et al. “Colchicine in Patients with Chronic Coronary Disease.” New England Journal of Medicine. 2020. 

Jolly SS, d’Entremont MA, Lee SF, et al. “Colchicine in Acute Myocardial Infarction.” New England Journal of Medicine. 2025. 

Abela GS, Aziz K. “Cholesterol Crystals Piercing the Arterial Plaque and Intima Trigger Local and Systemic Inflammation.” Journal of Clinical Lipidology. 2010. 

American College of Cardiology. “Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement.” Journal of the American College of Cardiology. 2025. 

Dicks L, et al. “Effect of an (–)-Epicatechin Intake on Cardiometabolic Parameters: A Systematic Review of Randomized Controlled Trials.” Nutrients. 2022. 

Other articles you may enjoy

Chronic Inflammation 101
Polyphenols & the Microbiome
Inflammation’s Role in Disease
Metabolic-Inflammatory Tone
Brain-Body Resilience

Note: Always consult with a healthcare professional before considering any treatment options or significant dietary changes.